Decisions about systemic treatment are increasingly based on more detailed knowledge of the primary tumor characteristics like amplification or over-expression of HER2 [29] and hormone receptor positivity [30], which improves the patient outcomes. This evidence concerns the gene ERBB2 and neoplasm.